P477Experience with dulaglutide in a real‐world settingS ZOURAS1, JW Stephens1,2, DE Price1 and W Syed11Department of Diabetes & Endocrinology, Morriston Hospital, ABM University Health Board, Swansea, UK, 2Diabetes Research Group, University of Swansea, Swansea, UKAims: Dulaglutide is a once weekly administered glucagon‐like peptide (GLP)‐1 analogue, which is now available for use in the United Kingdom. We examined the clinical benefits of treatment with dulaglutide in a sample of secondary care patients attending our local diabetes clinic.Methods: All patients commenced on dulaglutide at Morriston Hospital are routinely monitored to assess the efficacy of the product. Glycaemic control, weight and the use of other concomitant therapies are recorded as part of their follow‐up. To date, 21 patients with Type 2 diabetes have been initiated on dulaglutide with six‐month follow‐up data available.Results: The mean age of the sample was 59 ± 13 years and comprised of 16 males and 5 females. Baseline weight and HbA1c were 115.0 ± 23.6 kg and 79.1 ± 4 mmol/mol respectively. At six months the respective values were 112.32 ± 5.5 kg (p = 0.007) and 70 ± 18 mmol/mol (p = 0.03). No statistical changes were observed for serum creatinine, eGFR, triglyceride and albumin:creatinine ratio. Of interest, a significant reduction was seen in total cholesterol from 4.4 ± 1.2 mmol/l to 4.1 ± 1.2 mmol/l (p = 0.01). Of note, four patients were
Diabetic Medicine – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera